We conclude that the expression of Tdt or CD7 is associated with an unfavorable outcome and that the combination of both defines a clinical subset with a poorer prognosis due to the significantly higher association with MDR phenotype, and 'poor prognostic' chromosomal abnormalities.
Introduction
Immunophenotyping represents a widely used method to diagnose and classify acute leukemias complementing morphology and cytochemistry. 1 Evaluation of surface and intracellular antigens allows identification of lineage commitment and the stage of maturation of the cell involved in the leukemic process. 2, 3 The systematic use of monoclonal antibodies (moAbs) has also allowed detection of inappropriate expression of antigens from more than one lineage, thus raising the possibility of 'lineage infidelity' or 'lineage promiscuity'. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Recognition of lymphoid antigen (LyAg)-positive AML is potentially useful for immunological detection of minimal residual disease, [20] [21] [22] [23] [24] but the prevalence and prognostic importance of LyAg expression in AML remain controversial. 5, 10, 11, [13] [14] [15] 17, [25] [26] [27] [28] [29] [30] In a previous study of 154 patients, we found that certain phenotypic subgroups had a worse prognosis based on the expression of CD7. 13 In the present study, we extend these findings and report on the expression Correspondence: A Venditti, Cattedra di Ematologia, Università 'Tor Vergata', Divisione di Ematologia, Ospedale S Eugenio, Piazzale Umanesimo 10, 00144 Rome, Italy; Fax: 39 6 5915965 Received 11 August 1997; accepted 20 March 1998 of LyAg in 335 unequivocal cases of AML. We have found that Tdt + and/or CD7 + AML represents a distinct entity with an unfavorable outcome, possibly due to the coordinate occurrence of GP-170 and poor prognostic chromosomal abnormalities.
Patients and methods

Patients and treatments
The 335 consecutive patients with newly diagnosed AML 31 included in this study were admitted to our institution between June 1987 and May 1997. No patients had a history of prior therapies with anticancer drugs or a diagnosis of myelodysplastic syndrome. Antileukemic treatment was differentiated according to age. Among patients aged over 60 years, 98 were given a combination of Ara-C (1 g/m 2 /day) for 6 days and mitoxantrone (6 mg/m 2 /day) for 6 days as remission induction therapy and 20 received Ara-C (100 mg/m 2 /day) for 7 days, etoposide (100 mg/m 2 /day) for 3 days and mitoxantrone (7 mg/m 2 /day) for 3 days, according to the EORTC/GIMEMA protocol AML-13. Among patients aged less than 60 years, 122 received Ara-C (200 mg/m 2 /day) for 7 days combined with daunorubicin (45 mg/m 2 /day), while 61 were treated with Ara-C (100 mg/m 2 /day) for 7 days, etoposide (100 mg/m 2 /day) for 5 days and daunorubicin (50 mg/m 2 /day), either idarubicin (10 mg/m 2 /day) or mitoxantrone (7 mg/m 2 /day) for 3 days according to the Amgen protocol G-CSF 91134 or EORTC/GIMEMA protocol AML-10. Patients with promyelocytic leukemia (APL), regardless of age, received an induction course either with idarubicin (10 mg/m 2 /day) for 6 days alone or associated with Ara-C (n = 24), or idarubicin 12 mg/m 2 /day for four doses plus alltrans retinoic acid 45 mg/m 2 /day (n = 10). 32 All patients achieving CR were given an anthracyline-based post-induction regimen, even including cytosine-arabinoside and etoposide. CR was defined by a bone marrow (BM) with less than 5% blasts and restored normal hematopoiesis. Remission failures were divided into three categories as previously described. 33 (1) early death, ie patients who died of infection or hemorrhage within 7 days after the end of chemotherapy; (2) death in hypoplasia; and (3) resistant disease, ie patients who survived for 13 days or more and whose leukemic cells were continuously present in their BM, or whose leukemic cells were cleared from their BM during or after therapy, but reappeared before the resumption of normal hematopoiesis. Relapse was defined as reappearance of blasts in the blood or the finding of more than 5% blasts in the BM, not attributable to other causes (eg BM regeneration).
Diagnostic criteria
The 335 patients (186 men and 149 women) enrolled in this study were diagnosed to have de novo AML. Diagnosis of AML was confirmed by MPO expression and lack of cCD3 and cCD22. Other biologic and clinical features are summarized in Table 1 .
Immunophenotyping
Bone marrow and peripheral blood samples for this study were obtained under local institutional review board protocols. Surface antigens were detected by double/triple-color immunofluorescence assay combining phycoerthrin (PE), fluorescein isothyocyanate (FITC) and peridin chlorophyll protein (PerCP) conjugated monoclonal antibodies (Moabs). These included: CD33 PE, CD13 PE, CD14 PE, CD19 PE, CD20 PE purchased from Coulter (Hialeah, FL, USA); CD33 PE, CD13 PE, CD14 PE, CD34 FITC/PE/PerCP, CD15 FITC, CD7 FITC, CD3 FITC/PerCP, CD4 FITC, CD8 PE, CD2 PE, CD5 PE, CD10 FITC, CD19 FITC/PE, CD22 PE, CD20 FITC, CD11b PE, CD11c PE, HLA-DR PerCP, Leu54 PE, CD56 FITC/PE, CD61 FITC, CD62 PE purchased from Becton Dickinson (San Jose, CA, USA); CD41 FITC, CD42 FITC purchased from Immunotech (Marseille, France). Mononuclear cells from peripheral blood and/or bone marrow samples were separated on Fycoll-Hypaque density gradient and washed three times in phosphate-buffered saline solution (PBS). The samples contained у80% of blasts, as confirmed with MayGrü nwald-Giemsa preparation, and were analyzed within 24 h from collection or cryopreserved with 10% fetal calf serum and 10% dimethyl sulfoxide and analyzed later after quick thawing. The viability, as assessed by trypan blue exclusion, was Ͼ95%. Before antibody staining, cells were incubated with human AB serum (100 l/ml) for 10 min at room temperature to minimize the Fc receptor binding. After a further wash, cells were resuspended in PBS at a final concentration of 10 × 10 7 /ml. Each Moab was incubated with 10 6 no changes were observed in the percentage of positivity for a given lymphoid marker. For the cases which did not express CD34, the double staining was performed associating the lymphoid marker which tested positive with a myeloid one. The double/triple stained samples were analyzed with the Paint-a-Gate program. This program provides multidimensional, multicolour analysis of FACS-acquired list-mode data files. It allows classification of events by painting them different colors and then quantifying these populations as a percentage of the total events. This is in order to visualize in different plots cell populations which are difficult to see in two dimensions. To investigate cytoplasmic/nuclear antigens the following reagents were also used: CD3, anti-MPO (␣MPO), polyclonal TdT supplied by Technogenetics (Milan, Italy), and CD22 obtained from Becton Dickinson. To visualize TdT, cytoplasmic CD3 and CD22 and ␣MPO cytocentrifuge preparations were fixed in cold methanol for 30 min (nuclear staining) or acetone for 5-10 min at room temperature (cytoplasmic staining). After incubation with the primary Moab and the second layer for 30 min, the slides were washed in PBSA and mounted with glycerol:PBS 1:1 and a coverslip. ␣MPO was also revealed by using the alkaline phosphatase anti-alkaline phosphatase (APAAP) method as previously described. 14, 15 Since 1994, intracellular antigens have also been investigated by flow cytometry using Ortho PermeaFix (OPF) according to the manufacturer's recommendations. 34 Tdt was regarded as positive when at least 20% of gated cells were more fluorescent than the isotypic control. Cases with a simultaneous expression of MPO, cCD3 and/or cCD22 were classified as genuine 'biphenotypic' leukemias and not included in the present study. We also tested expression of the multidrug-resistance P-glycoprotein (GP-170) (C219 FITC obtained from Centocor, Malvern, PA, USA) in 224 samples. As C219 reacts with an epitope located on the inner surface of the cell membrane, cells were fixed and permeabilized in 3% paraformaldehyde/PBS and 50% cold acetone/PBS. Samples were then incubated at +4°C for 30 min with 10 l of unconjugated C219 (final concentration: 10 g/ml). After two washings in PBSA, cells were further incubated at +4°C with an FITC-conjugated F(ab) 2 fragment of goat antimouse Ig (dilution 1:20; Technogenetics, Milan, Italy). Negative controls were performed by incubating cells with an isotype antibody (IgG2a). Analysis was performed by flow cytometry as mentioned above. In parallel, 130 of our cases were tested for the expression of GP-170 using other MoAbs (4E3, MRK16 and UIC2) and no relevant differences were noted in terms of positivity compared to C219.
Cytogenetics
Procedures for cytogenetic evaluation have been previously described in detail. 35 We performed a methotrexate cell synchronization technique and a direct preparation, and examined the chromosomes after Giemsa stain. Whenever possible, at least 20 metaphases were analyzed. Karyotypes were classified in agreement with the guidelines of the International System for Human Cytogenetic nomenclature. 36 The detection of a minimum of two metaphases with an identical rearrangement or extra chromosome was regarded as evidence of the existence of an abnormal clone. Complex karyotypes were defined by the presence of three or more events of translocation and nondisjunction in the same clone 37 or by the presence of multiple unrelated clones.
Statistical analysis
Relationship of the expression of biological data to quantitative parameters (age, blood counts, percentage of marrow blasts) was studied by analysis of variance (ANOVA). Relationship of marker expression to patient's characteristics and response to treatment were estimated by two-sided 2 test (or Fisher's exact test when either group included fewer than 20 cases). A P value of 0.05 or less was considered to be significant. Since each patient category was assigned to a specific therapeutic protocol, the effects of treatment were specifically factored before significance was assigned. The Kaplan-Meier product-limit was used for estimation of survival (SV) and continuous CR (CCR) duration. SV was calculated from the date of diagnosis to the date of death or last follow-up. CCR was measured from achievement of CR until relapse or death in remission. Patients undergoing bone marrow transplantation were censored at the time of marrow infusion. For comparison of survival and remission duration of two or more groups, the log-rank test was applied. To evaluate the simultaneous impact of different variables on duration of SV and CCR, a multivariate analysis was performed using the Cox regression model. Conversely, a stepwise regression model was used to assess the effect of different variables on achievement of CR. Only variables for which univariate analysis had shown a significant association were considered in the multivariate analysis.
Results
Immunophenotype
Overall 41% (137/333) of our cases expressed lymphoid antigens; this figure did not take into account Tdt and CD7 which were analyzed separately as no longer considered specific for lymphoid lineage. Incidence of CD2, CD4, CD5, CD10, CD19, CD20 and CD56 and their relationship with FAB classes are showed in Table 2 . Only CD4 and CD56 showed a statistically significant association with M4 and M5 AML (P = 0.013 and 0.022, respectively.
Tdt expression ( Table 2) :
The expression of Tdt was heterogeneous in terms of number of cells positively stained ranging between 21 and 80%. Moreover, its mean fluorescence intensity was quite uniformly dim and markedly weaker than that observed in lymphoblastic leukemia. In this view no cases with bright Tdt expression could be identified, and the analysis was based on a positive-negative fashion model. Tdt was positive in 80/321 evaluable cases (25%). It was significantly associated with more immature FAB classes such as M0 and M1 (P Ͻ 0.001), accordingly a significant correlation between Tdt and CD34 was found (P = 0.001). Sixty-six percent of Tdt positive cases also expressed GP-170 but the association was not statistically significant (P = 0.08). No significant correlations were observed between Tdt and lymphoid antigens such as CD2, CD4, CD5, CD10, CD19, CD20 and CD56, as well as between Tdt and sex, age, extramedullary disease or WBC higher than 50 × 10 9 /l. CD7 expression (Table 2) : CD7 was expressed in 102/332 (31%) cases tested. It was significantly correlated with the FAB classes M0, M1 and M5 (P = 0.018), with CD34 (P Ͻ 0.001) and GP-170 (P Ͻ 0.001). Forty-five percent of CD7-positive patients had a WBC у50 × 10 9 /l (P = 0.009), while no correlations were found with lymphoid antigens such as CD2, CD4, CD5, CD10, CD19, CD20 and CD56 or with other clinical parameters such as sex, age or extramedullary disease.
Cytogenetic analysis
Karyotypes were available in 221 of the 335 cases (66%) and revealed chromosomal defects in 170 (77%) of them. As expected, a significant correlation (P = 0.001) was observed between certain chromosomal abnormalities and specific FAB subsets (Table 3) : t(15;17) was exclusively associated with M3 subtype; t(8;21) was seen in M2 cases but 2; 6 of 13 t(9;22) belonged to the M1 subset. Twenty-four of 30 cases of anomalies of chromosome 5 and/or 7 were detected in the FAB categories M0, M1 and M2, and finally 11/15 rearrangements of chromosome 11 at band q23 were consistent with myelomonocytic/monocytic differentiation. In order to gain prognostic indications linked to the expression of Tdt or CD7, correlations of these markers with specific karyotypic abnormalities were investigated. Eight of 13 cases (61%) with t(9;22) and 11/26 (42%) with anomalies of chromosome 5 and/or 7 were Tdt positive (P Ͻ 0.0001). Only one (7%) case of rearrangement at 11q23 was Tdt-positive. Eight of 13 cases (61%) with t(9;22), 12/30 (40%) with anomalies of chromosome 5 and/or 7 and 5/15 (33%) with rearrangements 11q23 were CD7 positive (P = 0.025). Conversely, cases with t(8;21) were Tdt and CD7 negative; cases with t(15;17) were Tdt negative and only 9% (3/34) were CD7 positive (Table 4) .
Prognostic features:
Clinical data are reported in Table 1 . CR was achieved in 152 patients out of 299 assessable for response (51%). Median duration of survival and CR was 51 and 61 weeks, respectively. When considering the CR rate in relation to Tdt and CD7 expression, a significant difference was observed between negative and positive cases; Tdt-negative patients had a CR rate of 58 vs 34% of Tdt-positive (P Ͻ 0.001), while CR rate for CD7-negative patients was 56 vs 40% of CD7-positive (P = 0.013). Even survival rates were significantly shorter for patients expressing Tdt or CD7 (23) (P = 0.006 and 0.001, respectively) (Figure 1a and b) . No significant differences were observed as regard to CCR between patients Tdt or CD7 positive or negative. Multivariate analysis was also performed to test the simultaneous effect of age (Ͻ60 or Ͼ60 years), WBC, FAB, karyotype, CD7, Tdt and GP-170 on CR rate, overall survival and CCR. Variables were entered into the model and non-significant factors were removed in a stepwise fashion followed by a re-estimation of effects and significance at each step. Tdt emerged as an independent factor affecting CR achievement (P = 0.018) together with WBC (P = 0.001), age (P Ͻ 0.001), FAB (P = 0.012), karyotype (P Ͻ 0.001) and GP-170 (P Ͻ 0.001). With regard to survival, the independent role of GP-170 (P = 0.001), FAB (P = 0.001) and karyotype (P = 0.018) was confirmed. Karyotype and CD7
were found to adversely affect CCR (P = 0.001 and 0.037, respectively) ( The overall survival of cases CD7 + (a) and Tdt + (b) as compared to negative ones.
Table 5
The The results of multivariate analysis, aimed at evaluating the simultaneous impact on CR rate, overall SV and CCR of age, FAB, WBC, karyotype, GP-170, Tdt and CD7, are shown. Tdt and CD7 emerged as independent factors affecting CR achievement and duration of SV, respectively.
characterized by the greatest concentration of poor prognosisrelated factors and which we have already mentioned above to be associated with Tdt or CD7, although at lower frequency (Table 6 ). In fact, cases [Tdt
show the most frequent association with MDR phenotype (77% of the cases) (P = 0.003), deviant expression of LyAg (69% of the cases) (P Ͻ 0.001), chromosome PhЈ or anomalies of chromosome 5 and/or 7 (50% of the cases) (P Ͻ 0.001). No association was found with rearrangements at band 11q23. 
Discussion
The purpose of this study was to analyze the pattern of LyAg expression in a large series of AML and determine its clinical implications. The incidence of LyAg in our series (41%) was comprised within the ranges reported in the literature. Expression of CD2, CD5, CD10, CD19, and CD20 lacked any significant prognostic impact or classificative relevance, while CD4 and CD56 were significantly associated with M4 and M5 subtypes cases (Table 2 ). In particular we have not observed the association between immunophenotype and karyotype reported in the CALGB and EORTC studies, 43, 44 probably because of the smaller number of our cases (Table 4) . Tdt was significantly associated with AML-M0, M1 and CD34 thus confirming its link with immature leukemias. [7] [8] [9] [10] [11] 14, 15 CD7 was significantly associated with AML-M0, M1, M5, with CD34 and GP-170 45 in line with other reports which have also postulated the expansion of a pluripotent CD7
+ precursor in immature AML.
12,24,46,47 A significant proportion of patients whose blasts expressed Tdt or CD7 failed to enter a CR (P Ͻ 0.001 and 0.013, respectively) and experienced a shorter survival (P = 0.006 and 0.001, respectively) ( Figure 1a and b) ; in addition, in a multivariate analysis, Tdt and CD7 expression were found to adversely affect achievement and duration of CR (P = 0.018 and 0.037, respectively (Figure 2a, b and c) . These results reaffirm the poor prognostic role of CD7 expression in AML, 5, 13 and highlight the prognostic importance of Tdt expression. 48 We speculate that the expression of Tdt, CD7 or both reflect variable stages of leukemic immaturity. Indeed, the [Tdt ] which have a significant lower incidence of PhЈ, defects of chromosome 5/7, LyAg and involve basically AML-M2, M3 and M4. Of note, is the significant presence of t(9;22) or defects in chromosomes 5 and/or 7 linked to the dual expression of CD7 and Tdt (Table 5 ). This raises the issue of the relative contribution of the diverse molecular factors to net clinical outcome. While t(9;22) and defects in chromosomes 5 and/or 7 are themselves powerful predictors of poor clinical outcome it is conceivable that additional mechanisms of chemoresistance operationally connected to Tdt may be active in the leukemic cells. One of these mechanisms might be bcl-2-related (Dr G Del Poeta, unpublished observation).
The contribution of CD7 in this dual model seems strictly related to the expression of GP-170. All together these data indicate that Tdt + and/or CD7 + AML are prone to retain signs of immaturity and infidelity and that the presence of Tdt and CD7 as a single marker or in combination may correspond to different degrees of such immaturity/infidelity. The data presented are also of some interest since biologic similarities between de novo CD7 + and/or Tdt + AML and secondary leukemia are evident. Secondary AML frequently occurs in the elderly (over 60 years) and expresses an MDR phenotype within the context of multiple and non-specific abnormalities that are cytogenetically complex and associated with gain and loss of certain chromosomal regions (eg abnormalities of chromosome 5/7). [49] [50] [51] [52] Our phenotypic subgroups fit exactly this criteria. Our findings are also consistent with the results published by Cuneo et al 53 and Carbonell et al 54 who demonstrated that among biphenotypic leukemia, in the context of a general heterogeneity, some chromosomal abnormalities appeared to be more common: t(9;22), 11q23 rearrangements and defects of chromosome 5/7. Therefore, we conclude that the expression of typical LyAg in AML lacks prognostic value, while Tdt and/or CD7, no longer regarded as genuine lymphoid markers, design a 'discrete' entity which closely resembles secondary leukemias and whose dismal outcome may be attributed to the convergence of factors such as GP-170, t(9;22), defects of chromosome 5/7, immaturity and marked degree of lineage infidelity. This observation also indicates that certain chromosomal defects may lead to treatment failure since they are intrinsically associated with specific mechanisms of chemoresistance, such as GP-170 and abrogation of apoptosis. Banker et al 55 have recently demonstrated that some cytogenetic groups such as del (7) show consistently low apoptosis, both spontaneously or after exposure to chemotherapeutic agents in vitro. In this view, the expression of Tdt and/or CD7 may represent the phenotypic counterpart of cytogenetic and chemoresistance patterns which need to be searched for in order to deliver therapies as tailored as possible, even including MDR modulators, apoptosis-inducers and stem cell transplantation.
